ClinicalTrials.gg
CompletedNCT00220727Updated Apr 27, 2016Results posted

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

A Phase 2 interventional study of Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified in Purpura, Thrombocytopenic, Idiopathic, sponsored by Grifols Therapeutics LLC. Completed at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-27.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic — 3 open to participants now, 3 under way, 1 of them phase 3. Immunoglobulins, Intravenous · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
13th of 13
8 · median 40
Started
2003
with 1 other
Phase 2
3 of 13
1 open now
Registered
3rd of 13
by date
Lead sponsor
1 of 13
Grifols Therapeutics LLC

Among the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, this one is the 13th largest by enrollment, is one of 2 that started in 2003, is one of 3 in phase 2, and was the 3rd registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

3 of the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at two different infusion rates.

Read the detailed description

This is a prospective, randomized, single-center, open, cross-over trial in patients with a confirmed diagnosis of Idiopathic Thrombocytopenia Purpura (ITP). ITP is defined as isolated thrombocytopenia in a patient with no other clinically apparent associated conditions or factors that are known to cause thrombocytopenia as defined by the ITP Practice Guidelines Committee of the American Society of Hematology.

Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) at a dose of 1.0 g/kg will be given on 2 occasions as a single daily infusion for platelet counts \< 30,000 microliters (uL) or if clinically indicated, at maximum intervals of six weeks. Eligible patients will be randomized into one of two cross-over groups. Patients randomized to Group 1 will receive their first IGIV-C infusion at a rate of 0.08 mL/kg/min and their second infusion at a rate of 0.14 mL/kg/min. Conversely patients randomized to Group 2 will receive their first IGIV-C infusion at a rate of 0.14 mL/kg/min and their second infusion at a rate of 0.08 mL/kg/min according to the following schema:

Group 1:

  • Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min)
  • Infusion #2 (Week \<6) IGIV-C (0.14 mL/kg/min)

Group 2:

  • Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min)
  • Infusion #2 (Week \<6) IGIV-C (0.08 mL/kg/min)
03

Conditions studied

  • Purpura, Thrombocytopenic, Idiopathic

Keywords

  • Idiopathic (Immune) Thrombocytopenic Purpura
  • Immunoglobulin G
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from patient or legal guardian (according to institutional review board requirements)obtained prior to initiation of any study related procedures
  • Male and female subjects age between 12 and 75 years
  • Confirmed diagnosis of ITP logged in medical records available prior to entry into the trial.
  • Patients must have a count \< 30 x Giga/L (this level can be higher if clinically indicated).
  • Previously splenectomized patients may be included.
  • Any previously conducted bone marrow aspirations if conducted following diagnosis of ITP must be consistent with the ITP diagnosis (increased or normal levels of megakaryocytes in otherwise normal bone marrow).

Exclusion criteria

Exclusion Criteria:

  • History of allergic or other reaction to human gamma globulin or other plasma proteins and/or blood products.
  • Female patient who is pregnant or lactating or is not on an adequate program of if of .
  • Documented history of selective immunoglobulin A (IgA) deficiency (serum \<5.0 mg/dL) and known antibodies to IgA.
  • Currently on intermittent prednisone therapy. Prednisone therapy is allowed only if the patient has been on stable daily doses of prednisone for the preceding month and maintains the same treatment regimen throughout the study.
  • Renal or liver impairment defined by creatinine > 2.5 mg/dL, or direct >1.5 X the or liver transaminases ( or ALT) > 3 times the upper limit of normal.
  • Received anti-D or IGIV infusions within the past 14 days
  • Pre-treatment with the exception of acetominophen, routinely required to control/ameliorate IGIV infusion-related adverse events (AEs), or any patient who has been, unresponsive to IGIV therapy for their ITP
  • History or clinical evidence of medical conditions felt to be the underlying cause of their thrombocytopenia. Such conditions commonly include systemic lupus erythematosus, history of chronic lymphocytic leukemia, dysplasia, agammaglobulinemia, treatment with heparin, quinidine, quinine, trimethoprim-sulfamethoxazole, or ticlopidine or any other drug thought to be the cause of patient's thrombocytopenia, congenital or hereditary thrombocytopenia, or pseudothrombocytopenia (clumping on peripheral blood smear)
  • Conditions that could alter protein catabolism and/or immunoglobulin G (IgG) utilization (e.g. protein-losing enteropathies, nephrotic syndrome)
  • Congestive heart failure ( Stage III or IV)
  • Diabetes mellitus
  • Paraproteinemia
  • Concomitant nephrotoxic drugs
  • level more than 2g/L below the lower limit of normal.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Group 1

    Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week \<6) IGIV-C (0.14 mL/kg/min)

    Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified

  • Experimental
    Group 2

    Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week \<6) IGIV-C (0.08 mL/kg/min)

    Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified

Interventions

  • DrugImmune Globulin IV [Human], 10% Caprylate/Chromatography Purified

    Drug page: Immunoglobulins, Intravenous

    IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.

    Also known as: Gamunex®, IGIVnex®, Gaminex, IGIV-C, IGIV-C, 10%, IVIG, BAY 41-1000, TAL-05-00004, Immune Globulin (Human), 10% (IGIV), Immune Globulin Intravenous, 10% by Chromatography Process, NDC 13533-645-12, NDC 13533-645-15, NDC 13533-645-20, NDC 13533-645-24, NDC 13533-645-71

06

What researchers measure

Primary outcomes

  1. Free Hemoglobin

    Free hemoglobin as a measure to assess hemolysis.

    Time frame: 24 hours after treatment

  2. Hematocrit

    Hematocrit as a measure to assess hemolysis

    Time frame: 24 hrs after treatment

  3. Red Blood Cells

    Red blood cells as a measure to assess hemolysis

    Time frame: 24 hrs after treatment

  4. Change From Baseline in Platelet Levels

    Time frame: 24 hours Post infusion and Day 7

Secondary outcomes

  1. Number of Subjects With Infusion Related Adverse Events

    Time frame: 48 hours after treatment

07

Results

Posted Aug 20, 2014

Participant flow

Single-center, open label study in patients with a confirmed diagnosis of Idiopathic Thrombocytopenic Purpura (ITP).

First Infusion (Week 0)
Participant flow — First Infusion (Week 0)
MilestoneIGIV-C, 10% - 0.08/0.14 mL/kg/MinIGIV-C, 10% - 0.14/0.08 mL/kg/Min
Started44
Completed44
Not completed00
Second Infusion (Week <6)
Participant flow — Second Infusion (Week <6)
MilestoneIGIV-C, 10% - 0.08/0.14 mL/kg/MinIGIV-C, 10% - 0.14/0.08 mL/kg/Min
Started44
Completed34
Not completed10
Withdrew: Pt did not meet study requirement10

Outcome measures

PrimaryFree Hemoglobin

Free hemoglobin as a measure to assess hemolysis.

Time frame:
24 hours after treatment
Reported as:
Mean · g/dL
Free Hemoglobin
g/dLIGIV-C, 10% (0.08 mL/kg/Min)IGIV-C, 10% (0.14 mL/kg/Min)
Free Hemoglobin13.057 ± 1.77812.371 ± 2.644
SecondaryNumber of Subjects With Infusion Related Adverse Events
Time frame:
48 hours after treatment
Reported as:
Number · participants
Number of Subjects With Infusion Related Adverse Events
participantsIGIV-C, 10% (0.08 mL/kg/Min)IGIV-C, 10% (0.14 mL/kg/Min)
Number of Subjects With Infusion Related Adverse Events23
PrimaryHematocrit

Hematocrit as a measure to assess hemolysis

Time frame:
24 hrs after treatment
Reported as:
Mean · percentage of blood
Hematocrit
percentage of bloodIGIV-C, 10% (0.08 mL/kg/Min)IGIV-C, 10% (0.14 mL/kg/Min)
Hematocrit36.80 ± 4.71135.043 ± 6.793
PrimaryRed Blood Cells

Red blood cells as a measure to assess hemolysis

Time frame:
24 hrs after treatment
Reported as:
Mean · 10^12 cells/L
Red Blood Cells
10^12 cells/LIGIV-C, 10% (0.08 mL/kg/Min)IGIV-C, 10% (0.14 mL/kg/Min)
Red Blood Cells4.1514 ± .48204.0786 ± 0.8258
PrimaryChange From Baseline in Platelet Levels
Time frame:
24 hours Post infusion and Day 7
Reported as:
Mean · Giga/L
Change From Baseline in Platelet Levels
Giga/LIGIV-C, 10% (0.08 mL/kg/Min)IGIV-C, 10% (0.14 mL/kg/Min)
Baseline29.50 ± 28.476.86 ± 3.39
24 hours post infusion21.17 ± 35.4942.29 ± 12.41
Day 776 ± 138.35118.7 ± 165.80

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV-C, 10% - 0.08 mL/kg/Min—0/8 (0%)8/8 (100%)
IGIV-C, 10% - 0.14 mL/kg/Min—0/7 (0%)7/7 (100%)
Most frequent other events
Most frequent other events
EventIGIV-C, 10% - 0.08 mL/kg/MinIGIV-C, 10% - 0.14 mL/kg/Min
HeadacheNervous system disorders5/84/7
UrticariaSkin and subcutaneous tissue disorders2/82/7
ArthralgiaMusculoskeletal and connective tissue disorders2/81/7
RashSkin and subcutaneous tissue disorders2/81/7
DizzinessNervous system disorders0/81/7
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders1/81/7
Abdominal DistentionGastrointestinal disorders1/80/7
DiarrhoeaGastrointestinal disorders1/80/7
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders1/80/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IGIV-C, 10% - 0.08/0.14 mL/kg/MinIGIV-C, 10% - 0.14/0.08 mL/kg/MinTotal
<=18 years000
Between 18 and 65 years347
>=65 years101
Age, Continuous
Age, Continuous(years)IGIV-C, 10% - 0.08/0.14 mL/kg/MinIGIV-C, 10% - 0.14/0.08 mL/kg/MinTotal
Mean47.75 ± 15.7847.50 ± 14.8947.63 ± 14.20
Sex: Female, Male
Sex: Female, Male(Participants)IGIV-C, 10% - 0.08/0.14 mL/kg/MinIGIV-C, 10% - 0.14/0.08 mL/kg/MinTotal
Female347
Male101
Region of Enrollment
Region of Enrollment(participants)IGIV-C, 10% - 0.08/0.14 mL/kg/MinIGIV-C, 10% - 0.14/0.08 mL/kg/MinTotal
United States448
08

Study locations

1 site
  • New York Presbyterian Hospital
    New York, New York 10021-4885, United States
09

References and documents

Publications

  • Bussel JB, Hanna K; IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. Am J Hematol. 2007 Mar;82(3):192-8. doi: 10.1002/ajh.20822. PubMed 17109385 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Oct 2003 and a completion of Oct 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 10 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
Start
Jul 2003
Primary completionActual
Oct 2003
CompletionActual
Oct 2003
Results first posted
Aug 20, 2014
Last update
Apr 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00220727
Responsible party
Sponsor
First posted
Sep 22, 2005
Start date
Jul 2003
Primary completion
Oct 2003
Completion
Oct 2003
Results posted
Aug 20, 2014
Last update
Apr 27, 2016

Study contacts

James Bussel, MD
principal investigator · New York Presbyterian Hospital-Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion